Wegovy (semaglutide) Wegovy is a GLP-1 agonist medication that is approved to: Aid in weight loss for adults and children over 12 years old who have obesity, or in adults who have overweight and have a weight-related health condition (such as high blood pressure, type 2 diabetes , or high cholesterol) Reduce the risk of major cardiovascular events, such as heart attack or stroke, in adults who have cardiovascular disease and have obesity or overweight Wegovy comes in a single-use pen that you inject once per week, either with or without food
GLP-1 treatment suppressed the level of TNF- in an Alzheimers disease animal model brain induced by injection of STZ (Solmaz et al., 2015)
When butyrate is present in the gut due to the activity of bacteria like Clostridium butyricum, it interacts with the intestinal cells to signal the release of more GLP-1
Side effects such as nausea, diarrhea, vomiting and constipation that are common early on may also drive people away
Resmetirom received FDA approval for the fibrotic stage, but the steatosis stage, where the vast majority of patients sit, has no approved pharmacological intervention
